drugset / Trial / NCT00002766

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

NCT00002766

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying two different chemotherapy regimens and comparing them to see how well they work in treating adults with acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.

Timeline

Start
1996-03
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified Intravenous
Subject Cytarabine Small molecule Intravenous
Subject Dactinomycin Protein / enzyme biologic Intravenous
Comparator Daunorubicin Small molecule Intravenous
Subject Doxorubicin Other / unclassified Intravenous
Subject Etoposide Small molecule Intravenous
Subject MERCAPTOPURINE ANHYDROUS Small molecule Oral
Subject Methotrexate Small molecule Other
Subject Mitoxantrone Small molecule Intravenous
Subject Pegaspargase Protein / enzyme biologic Intravenous
Subject Prednisone Other / unclassified Oral
Subject Vincristine Small molecule Intravenous
Subject carmustine Small molecule Intravenous
Background sargramostim Protein / enzyme biologic Subcutaneous

Indications